Search bioRxiv⌕ Search

Biology subjects

Cremer, I.

Publications and source records attributed to Cremer, I..

2 recordsLinked to original sources

3D vascularized microtumors unveil aberrant ccRCC vasculature and differential sensitivity to targeted treatments

Clear cell renal cell carcinoma (ccRCC) is largely driven by Von Hippel Lindau (VHL) protein deficiency, promoting epithelial-mesenchymal transition, invasion, and hypervascularization, mediated by vascular endothelial growth factor (VEGF) signaling resulting in a structurally abnormal capillary network, which remains insufficiently defined. Previous studies correlating patient outcome with microvascular density yielded diverse results, underscoring the limitations of conventional parameters to fully capture vascular complexity. While VEGF-targeted anti-angiogenic first-line therapies such as sunitinib prolong progression-free survival in metastatic ccRCC, their efficacy is hampered by resistance mechanisms. This study aims to elucidate the three-dimensional architecture of ccRCC-specific vasculature in the tumor microenvironment, and its response to targeted therapies. Analysis of human ccRCC samples identified two distinct vascular structures, markedly differing from tumor capillaries, termed ponds and sheets, which were further characterized in patient-derived xenografts using advanced 3D microscopy on optically cleared samples. Ponds are large, dilated, irregular structures with wide cavity, whereas sheets are thin, elongated, and collapsed structures. To further dissect endothelial network morphogenesis, we developed an innovative in vitro 3D vascularized microtumor model, faithfully recapitulating the aberrant pond architecture. Dynamic live imaging unraveled the temporal relationship between tumor invasion and pond morphogenesis. Additionally, drug sensitivity assays demonstrated that ponds exhibit lower responsiveness to sunitinib compared to tumor capillaries. Altogether, our 3D model not only captures a specific architecture of ccRCC vascular network but also provides mechanistic insight into its development and therapeutic sensitivity. This model offers a promising avenue for personalized treatment assessment and for identification of novel therapeutic strategies. Statement of significanceA co-culture-engineered model integrating tumor spheroid invasion and capillary morphogenesis recapitulates the ccRCC endothelial structures and their response to treatments.

cancer biology↗

Differential predictive value of resident memory CD8+T cell subpopulations in non-small-cell lung cancer patients treated by immunotherapy

A high density of resident memory T cells (TRM) in tumors correlates with improved clinical outcomes in immunotherapy-treated patients. However, in preclinical models, only some subpopulations of TRM are associated with cancer vaccine efficacy. We identified two main TRM subpopulations in tumor-infiltrating lymphocytes derived from non-small cell lung cancer (NSCLC) patients: one co-expressing CD103 and CD49a (DP), and the other expressing only CD49a (MP); both exhibiting additional TRM surface markers like CD69. DP TRM exhibited greater functionality compared to MP TRM. Analysis of T-cell receptor (TCR) repertoire and of the stemness marker TCF-1 revealed shared TCRs between populations, with the MP subset appearing more progenitor-like phenotype. In two NSCLC patient cohorts, only DP TRM predicted PD-1 blockade response. Multivariate analysis, including various biomarkers (CD8, TCF1+CD8+T cells, and PD-L1) associated with responses to anti-PD(L)1, showed that only intra-tumoral infiltration by DP TRM remained significant. This study highlights the non-equivalence of TRM populations and emphasizes the importance of distinguishing between them to better define their role in antitumor immunity and as a biomarker of response to immunotherapy.

immunology↗